The FDA approval of bevacizumab (Avastin ® , Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/ VEGFR pathway is a viable target for anti-angiogenesis tumor therapy, additional targets involved in tumor neovascularization have been identiWed. One promising target present speciWcally on tumor vasculature is endoglin (CD105), a member of the TGF-receptor complex expressed on vascular endothelium and believed to play a role in angiogenesis. Monoclonal antibody therapy and preventive vaccination against CD105 has met with some success in controlling tumor growth. This report describes the in vivo proof-of-concept studies for two novel therapeutic vaccines, Lm-LLO-CD105A and Lm-LLO-CD105B, directed against CD105 as a strategy to target neovascularization of established tumors. Listeria-based vaccines directed against CD105 lead to therapeutic responses against primary and metastatic tumors in the 4T1-Luc and NT-2 mouse models of breast cancer. In a mouse model for autochthonous Her-2/neu-driven breast cancer, Lm-LLO-CD105A vaccination prevented tumor incidence in 20% of mice by week 58 after birth while all control mice developed tumors by week 40. In comparison with previous Listeria-based vaccines targeting tumor vasculature, Lm-LLO-CD105A and Lm-LLO-CD105B demonstrated equivalent or superior eYcacy against two transplantable mouse models of breast cancer. Support is provided for epitope spreading to endogenous tumor antigens and reduction in tumor vascularity after vaccination with Listeria-based CD105 vaccines. Reported here, these CD105 therapeutic vaccines are highly eVective in stimulating anti-angiogenesis and anti-tumor immune responses leading to therapeutic eYcacy against primary and metastatic breast cancer.
Introduction
Tumor-associated neovascularization was Wrst documented as early as the 1940s [1, 2] . However, it was not until the work by Dr. Judah Folkman in the early 1970s that targeting this neovascularization, or "angiogenesis" as termed by Folkman, was postulated as a viable strategy for cancer therapy [3, 4] . Development of anti-angiogenesis therapies over the next few decades culminated in the Wrst commercially available angiogenesis inhibitor in 2004, bevacizumab (Avastin anti-angiogenesis therapy, evidence from preclinical studies suggests that active immunotherapy is also a promising and eVective alternative [6] [7] [8] [9] . Previous work by Seavey et al. and others demonstrates that tumor vasculature-associated proteins such as VEGFR2 can be eVectively targeted by CTL-based active immunotherapy that leads to tumor regression in mouse models of breast cancer [6, 8] . Recent studies oVer CD105 as a promising new target for anti-angiogenesis CTL-based active immunotherapy [9, 10] .
CD105 is a large transmembrane glycoprotein that plays a crucial role in TGF-signaling and angiogenesis [11] [12] [13] [14] [15] [16] . As a member of the TGF-receptor complex, it binds TGF-1 and 3 and forms a heterodimeric complex with TGF -RII to facilitate signal transduction [17, 18] . Expression of CD105 is enhanced upon TGF-stimulation and exposure to hypoxic conditions, such as those found in tumors [19] . The highest expression of CD105 is found on vascular endothelial cells, and studies suggest that the angiogenic properties of TGF-are dependent on CD105 expression [14, 15] . The importance of CD105 in angiogenesis is highlighted in observations found with CD105 knockout mice [12, 13, 20, 21] . In the absence of CD105, maturation of cardiac tissue vasculature is impaired, resulting in early embryonic death [12] . While the evidence is clear that CD105 is crucial for normal vascular development, there is a growing body of evidence that CD105 also plays an additional role in tumorigenesis [22] [23] [24] [25] .
The importance of neovascularization during tumorigenesis is well characterized, and CD105 is believed to be one of the factors involved in this process [22] [23] [24] [25] [26] . As a prognostic factor, CD105 protein can be detected in the serum of tumor-bearing patients and the levels of serum CD105 increase with metastatic severity [27, 28] . Additionally, immunohistochemical analyses suggest that CD105 is highly expressed in the vascular endothelium of tumor tissue while it is barely detectable in normal tissues [29] [30] [31] . In addition, tumor-speciWc expression of CD105 within vascular capillary beds has previously been utilized in several therapeutic strategies [9, 10, [32] [33] [34] . CD105-speciWc monoclonal antibodies fused to either a radioactive isotope or a toxic compound, can target tumor vasculature speciWcally and were shown to inhibit tumor growth in preclinical mouse models of breast cancer [32] [33] [34] . Previously reported studies suggest that CD105 can even be targeted in a CTL-mediated tumor immunotherapy approach. Preventive vaccination with a cDNA encoding for CD105 resulted in reduced neovascularization and a reduced tumor burden in a mouse model for breast cancer [9, 10] . These approaches strongly support a case for the use of a CD105-directed vaccine to target the tumor vasculature.
This report describes the successful targeting of the neovascularization of established tumors by two Listeria-based vaccines directed against CD105. Each vaccine, Lm-LLO-CD105A and Lm-LLO-CD105B, is eVective in halting tumor growth in two separate mouse models of breast cancer, while Lm-LLO-CD105A signiWcantly delays time to tumor progression in an autochthonous mouse mammary tumor model. In comparison with previous Listeria-based vaccines targeting antigens present in tumor vasculature, the Listeria-based CD105 vaccines are either similar or superior in eYcacy to each in treating established NT-2 and 4T1-Luc tumors. Vaccination against CD105 also resulted in secondary tumor-speciWc CTL responses in a process known as epitope spreading. The resulting impact on tumor growth and neovascularization demonstrate that Listeriabased vaccines are eVective for targeting CD105 expression on tumor vasculature in established tumors.
Materials and methods

Mice
Balb/c female mice (6-8 week old) were purchased from Charles River Laboratories, and FVB/NJ female mice (6-8 week old) were purchased from Jackson Laboratories. A rat Her-2/neu-transgenic mouse strain in the FVB/N background [35] used for prevention studies as a model for autochthonous breast tumor formation was housed and bred at the animal core facility at the University of Pennsylvania. All mouse experiments were performed in accordance with the regulations of the Institutional Animal Care and Use Committee of the University of Pennsylvania.
Construction of Lm-LLO-CD105A and Lm-LLO-CD105B
To construct the Listeria-based CD105 vaccines, mRNA was puriWed from 4T1-Luc cells and converted into cDNA. The regions of CD105 incorporated into each vaccine, as illustrated in Fig. 1a , were ampliWed from the total cDNA pool with the following primers: Lm-LLO-CD105A, (F) 5Ј-TAAT-CTCGAG-TATAGCTTTGTACCCACA-3Ј; Lm-LLO-CD105A (R) 5Ј-ATTA-ACTAGT-CAGGGAG ACATTGCTGAC-3Ј; Lm-LLO-CD105B (F), 5Ј-TAAT-CT CGAG-CAGCCAAAGTGTGGCAA; Lm-LLO-CD105B (R), 5Ј-ATTA-CCCGGG-GGCACCAAAGGTGATACC. XhoI sequences underlined for forward primers, and SpeI (ACTAGT) and SmaI (CCCGGG) sequence underlined for reverse primers. Each fragment amplicon was restrictionenzyme digested and ligated into the Listeria expression plasmid, pGG34. Each sequence was genetically fused downstream to the gene encoding truncated Listeriolysin O (tLLO) under the control of the hly promoter. Subsequently, each construct, pGG34-LLO-CD105A and pGG34-LLO-CD105B, was electroporated into the attenuated Listeria monocytogenes (Lm) strain, XFL7, and plasmid-containing colonies were selected for resistance on BHI/chloramphenicol plates. To conWrm proper construction of Lm-LLO-CD105A and Lm-LLO-CD105B, each vaccine was grown in BHI/chloramphenicol selection media and secreted proteins were precipitated with trichloroacetic acid. After boiling in SDS sample buVer, secreted proteins were subject to SDS-PAGE analysis and transferred to a PVDF membrane. Western analysis on the membrane was performed with anti-PEST antibody (speciWc for the N-terminus of Listeriolysin O) to conWrm secretion of tLLO-CD105 fusion proteins. The isogenic Listeria vaccine, Lm-LLO-NYESO-1, was administered in all experiments to provide a Listeria control that produced and secreted an antigen not found in the mouse models of breast cancer used in this manuscript. Additionally, Lm-LLO-NYESO-1 administration has little or no impact on tumor burden in each of these tumor models in previous studies [6] .
Tumor load study
Two mouse breast tumor cell lines were used in these studies. The FVB/N syngeneic NT-2 tumor cell line was developed from a spontaneously occurring mammary tumor in a FVB/N HER-2/neu-transgenic mouse [36] . The 4T1 tumor cell line is a 6-thioguanine-resistant cell line, which was derived from a mouse mammary tumor virus (MMTV)-induced spontaneous mammary carcinoma [37] . It was transduced with luciferase and kindly made available to us by Dr. Ellen Pure, The Wistar Institute [38] . FVB/N mice were implanted subcutaneously in the right 
Lung surface metastases
Lungs from the naïve group (n = 5) and each vaccinated group, control Lm (n = 7), Lm-LLO-CD105A (n = 7), and Lm-LLO-CD105B (n = 6), were removed from the 4T1-Luc tumor load study on day 32. Lung surface metastatic nodules per lung were then counted with a Nikon SMZ1B Zoom Stereomicroscope attached to a Fostec 8375 Illuminator and Ringlight. The data are reported as the number of lung surface metastases per animal. 8 CFUs of each vaccine. Lungs were removed on day 46, and lung tissue was manually separated into a single-cell suspension. After removal of red blood cells with ACK lysing buVer, remaining cells were resuspended in 100 l of PBS and added to a single well of a 96-well black polystyrene assay plate. Subsequently, 100 l of Bright-Glo Luciferase reagent was added to each well, and the plate was incubated at room temperature for 5 min. After incubation, the plate was read in a Luminoskan Ascent Reader (Thermo ScientiWc, Waltham, MA) and arbitrary light units collected. To approximate the number of metastatic tumor cells in lung tissue, a standard curve of 4T1-Luc tumor cells was created and used to calculate the approximate number 4T1-Luc tumor cells in each lung.
CD31 mRNA expression
At the end of the experiment, tumors from each group were excised, placed in RNAlater solution (Ambion, Austin, TX) and stored at 4°C. RNA was extracted from the tumor tissue with Qiagen RNeasy plus mini kits (Qiagen, Valencia, CA), and total RNA was reverse-transcribed into cDNA using Applied Biosystems High Capacity cDNA reverse transcription kit (Applied Biosystems, Forest City, CA). cDNA from each tumor was then subjected to qPCR analysis for expression of the vascular marker, CD31. The primers used for CD31 expression are as follows: qCD31. FORWARD 5Ј-CAGGACCAGGTGTTAGTGTT-3Ј and qCD31.REVERSE 5Ј-ACTCCTGATGGGTTCTGACT-3Ј. AmpliWcation of 18S ribosomal RNA was used for standardization of all samples. CFU/mouse) due to their increased virulence. Tumor size was measured by calipers twice weekly throughout the course of the experiment. Tumor and lung tissue was removed at experimental end on day 46. The tumor tissues were analyzed for CD31 mRNA expression by qPCR, and the lung tissues were analyzed for 4T1-Luc natural lung metastasis by light microscopy and luciferase activity. Tumor volume was calculated as (tumor diameter) 3 /2.
Comparison of Anti-angiogenesis
FVB/N Her-2/neu-transgenic autochthonous tumor study
The FVB/N Her-2/neu-transgenic mouse expresses the rat HER-2/neu proto-oncogene under the control of the mouse mammary tumor virus (MMTV) promoter as a result of which female mice develop autochthonous mammary tumors between 4 and 9 months of age [35, 40] . Six-weekold FVB/N Her-2/neu-transgenic mice were immunized intraperitoneally every 3 weeks until 21 weeks of age with 2 £ 10 8 CFUs of Lm-LLO-CD105A (n = 15), Lm-LLO-CD105B (n = 15), and Lm-LLO-NYESO-1 (n = 15) as a control vaccine together with untreated (n = 20) as a naïve control. After week 21, mice were monitored weekly for appearance of autochthonous mammary tumors.
Hemoglobin assay FVB/N mice were implanted with 10 6 NT-2 tumor cells mixed with Matrigel (100 l 10 6 NT-2 cells + 400 l Matrigel) subcutaneously in the right Xank (4 mice/group) and were immunized intraperitoneally on day 7, 14, and 21 with 2 £ 10 8 CFU of Lm-LLO-CD105A, Lm-LLO-CD105B, or Lm-LLO-NYESO-1 as a vaccine control along with a group of untreated mice as a naïve control. Matrigel plugs were removed on day 34 and added to 10 ml of RF10 medium. The resulting cell suspensions were centrifuged, and 1 mL of ACK lysing buVer was added to the pellet and incubated at room temperature for 5 min. The RBC lysates were transferred to microcentrifuge tubes and stored at ¡80°C. Balb/c mice were implanted with 2 £ 10 5 4T1-Luc cells mixed with Matrigel (100 l 2 £ 10 5 4T1-Luc cells + 400 l Matrigel) subcutaneously in the mammary fat pad. Mice were subsequently immunized intraperitoneally on day 4 and 11 after tumor implantation with 2 £ 10 8 CFU of Lm-LLO-CD105A, Lm-LLO-CD105B, or Lm-LLO-NYESO-1 as a vaccine control along with a group of untreated mice as a naïve control. Matrigel plugs were removed on day 20 and processed as described earlier.
Hemoglobin content was measured by the Enzo Hemoglobin Detection Kit according to the manufacturer's instructions (Enzo Life Sciences, Farmingdale, NY).
ELISpot analysis
The 96-well Wltration plates (Millipore, Bedford, MA) were coated with 15 g/ml of rat anti-mouse IFN-antibody (clone AN18, MABTECH, Mariemont, OH) in 100 l of PBS. After overnight incubation at 4°C, the wells were washed and blocked with culture medium containing 10% fetal bovine serum. For Supplemental Figure 1B , CD8-enriched splenocytes were pooled from each experimental group (n = 3) and added to wells along with irradiated splenocytes containing either media alone, media with rIL-2 (5 U/mL), or media with rIL-2 and one of the following CD105 peptides at 2 g/ml: CD105a-1 (DLQPVDPTR-GEVTFTTSQVS), CD105a-2 (ETREVFLVLVSNKNVFV KFQ), CD105a-3 (EARKLNASIVTSFVELPL), CD105a-4 (AATKGAITSIAALDDPQSIV), CD105a-5 (EGVSGHK EAYILRILPGSEA). After 78 h of incubation at 37°C and 5% CO 2 , remaining cells were transferred to the antibodycoated plates for overnight incubation. Subsequently, the plate was washed followed by incubation with 1 g/ml biotinylated IFN-antibody (clone R4-6A2, MABTECH, Mariemont, OH) in 100 l PBS at 4°C overnight. After washing, 100 l of 1:100 streptavidin-horseradish peroxidase in PBS was added and incubated for 1 h at room temperature. Spots were developed by adding 100 l of substrate after washing and incubating at room temperature for 15 min. Color development was stopped by washing extensively in tap water, and spot-forming cells (SFC) were counted on an ELISpot reader.
Statistical analyses
One-tailed Student's t-tests were performed comparing Lm-LLO-CD105A and Lm-LLO-CD105B vaccination to the control Lm vaccination, Lm-LLO-NYESO-1, for all tumor load study, tetramer analysis, luciferase activity, CD31 mRNA expression, and hemoglobin concentration data except Figs. 3 and 4 , wherein a two-tailed Student's t-test was performed using GraphPad Prism version 4.0a for Macintosh (San Diego, CA, www.graphpad.com). For  Fig. 2b , a log rank test was performed to determine signiWcance between control Lm and each of the CD105 vaccines.
SigniWcant P values for all comparisons are depicted in Wgures as follows: *P < 0.05, **P < 0.01, ***P < 0.001, and n.s. = not signiWcant.
Results
To determine whether an anti-tumor immune response can be generated against CD105, two relatively small regions of the gene were identiWed to fuse to our adjuvant protein, truncated LLO, for insertion into the vaccine vector (Fig. 1a, regions included in each vaccine are underlined) . The rationale for this strategy was based on previous observations that attenuated Listeria-based vectors have diYculty in secreting large recombinant proteins (data not shown). Additionally, initial attempts to construct a CD105 vaccine using a single large fragment of the gene resulted in poor secretion of the recombinant tLLO-CD105 protein (data not shown). The two regions chosen from CD105 to place into the vaccines were selected to include a number of predicted epitopes and to exclude hydrophobic regions of the protein that could impede the ability of the bacterium to secrete the antigen. The region of CD105 in the Lm-LLO-CD105A vaccine contains at least three predicted H-2K d epitopes. Additionally, the region placed into the Lm-LLO-CD105B vaccine contains at least two predicted H-2K d epitopes. Western analysis of secreted proteins by each vaccine (Fig. 1b) demonstrated eYcient production and secretion of LLO N-terminal-containing proteins at the proper sizes for tLLO-CD105A and tLLO-CD105B. However, while cultures contained equivalent CFUs of each attenuated Listeriabased vaccine (data not shown), there is relatively more secretion of antigen by Lm-LLO-CD105A in comparison with Lm-LLO-CD105B possibly due to increased hydrophobicity of the tLLO-CD105B fragment (Fig. 1b) . These results taken in total conWrm that Lm-LLO-CD105A and Lm-LLO-CD105B each eYciently produce and secrete their respective recombinant fusion proteins. EYcient secretion of the recombinant antigenic proteins from attenuated Listeria vaccines is important for inducing the CTL-mediated responses vital to anti-tumor immunity [41] .
In order to test the eYcacy of our CD105 vaccines in controlling tumor growth, each vaccine has been tested in three separate models for mouse breast cancer. The Wrst tumor model is the implantable tumor cell line NT-2 derived from the Her-2/neu-transgenic mouse [36] . After implantation into the hind Xank of syngeneic FVB/N mice, mice were subsequently vaccinated followed by 2-weekly boosts with each CD105 vaccine or a control vaccine and tumor volume monitored throughout. As seen in Fig. 2a , vaccination with either CD105 vaccine resulted in primary tumor stasis and a signiWcantly smaller tumor volume at experiment end in comparison with control Lm vaccination. The second mouse breast tumor model used in our study utilizes a Her-2/neu-transgenic mouse, wherein the neu oncogene is transcriptionally expressed under the MMTV promoter [35] . In this model, mice are vaccinated every 3 weeks starting at week 6 and ending at week 21 and subsequently monitored for tumor incidence thereafter. While all of the unvaccinated naïve mice and control-vaccinated mice developed autochthonous tumors by week 40, each group of mice vaccinated with Lm-LLO-CD105A and Lm-LLO-CD105B contained tumor-free mice at week 58, 20, and 6.7%, respectively (Fig. 2b) . In fact, Lm-LLO-CD105A vaccination signiWcantly increased median time to tumor incidence in comparison with control Lm vaccination, 52 days versus 32 days, respectively (P = 0.0003). The third mouse breast tumor model used in this study is the aggressive 4T1-Luc tumor cell line. Unlike NT-2, if implanted in the mammary tissue, 4T1-Luc will naturally metastasize to organs such as the lungs, spleen, and brain with noticeable metastases present within 3 weeks postimplantation [37, 38] . Lm-LLO-CD105A and B both signiWcantly control 4T1-Luc primary tumor growth as compared with unvaccinated and control-vaccinated mice (Fig. 2c) . Additionally, the number of visible surface metastases on the lungs of Lm-LLO-CD105A and B is signiWcantly reduced as compared with each control at the termination of the experiment on day 32 post-tumor implantation (Fig. 2d) . As an additional measure of 4T1-Luc metastases in the lungs of vaccinated mice, luciferase activity was also measured in lung lysates. Luciferase activity in the lungs of CD105-vaccinated mice was signiWcantly reduced in comparison with control mice suggesting reduced metastases in that organ (Fig. 2e ). These results demonstrate that Listeria-based vaccines targeting CD105 can be highly eVective immunotherapeutics in controlling primary as well as metastatic breast tumor burden.
To assess whether CD105 is a superior target for antivasculature tumor immunotherapy, we compared the eVectiveness of each Lm-LLO-CD105 vaccine against previously characterized anti-vasculature Listeria-based vaccines. The previously characterized anti-angiogenesis vaccines target either the pericyte-speciWc protein HMW-MAA, Lm-LLO-HMWMAA-C, or two regions of the vascular endothelial growth factor receptor 2, Lm-LLO-FLK-I1 and Lm-LLO-FLK-E2 [6, 7] . Tumor load studies were performed with each of the implanted mouse breast tumor models, NT-2 and 4T1-Luc, and the eYcacy of each vaccine determined by their ability to control growth of established primary tumors and limit metastatic spread. While each of the previous anti-angiogenesis vaccines is more eVective than control vaccination at reducing the growth of implanted NT-2 tumors, both vaccines targeting CD105 appear to be at least as eVective therapeutically (Fig. 3a, b, c) . In fact, Lm-LLO-CD105A vaccination performed signiWcantly better at reducing tumor volume at experiment end on day 53 versus the other anti-angiogenesis vaccines, Lm-LLO-HMWMAA-C (P = 0.0156), Lm-LLO-FLK-E2 (P = 0.0255), and Lm-LLO-FLK-I1 (P = 0.008) (Fig. 3d) . Similar results are obtained for each of these vaccines when compared in the 4T1-Luc tumor model (Fig. 4a) . After allowing for establishment of 4T1-Luc primary tumors in the mammary tissue and subsequent vaccinations, both CD105 vaccines perform just as eVectively at reducing primary tumor volume at experiment end as previous vaccines and, in comparison with Lm-LLO-FLK-E2, Lm-LLO-CD105A was signiWcantly more eVective (P = 0.015) (Fig. 4b) . While the control Lm vaccine signiWcantly reduced tumor volume against less established 4T1-Luc tumors (Fig. 2c, P < 0.0001) as expected based on previously published Wndings [42] , no signiWcant impact was found against more established tumors (Fig. 4b) . In addition to tumor volume, Lm-LLO-CD105A vaccination was also signiWcantly superior to each of the previous anti-angiogenesis vaccines at reducing the number of lung surface metastases in 4T1-Luc tumor-implanted mice (Fig. 4c) . These results suggest that each Listeria-based CD105 vaccine is just as eVective if not superior to previous Listeriabased anti-angiogenesis vaccines at reducing primary and metastatic tumor burden in mouse models of breast cancer.
Due to the superior anti-tumor eYcacy of Lm-LLO-CD105A, a preliminary analysis was performed to determine the generation of a CD105-speciWc immune response by Lm-LLO-CD105A. Regions with predicted CTL epitopes in the fragment contained within Lm-LLO-CD105A were synthesized as 20-mer peptides (Supplemental Fig. 1a) . Pooled splenocytes from either Lm-LLO-CD105A-vaccinated mice or naive mice were enriched for CD8 + T cells and co-cultured with irradiated splenocytes loaded with the 20-mer CD105 peptides, cd105a-1 though 5, and then assayed for IFN-production by ELISpot analysis after 78 h. Stimulation with two of the peptides, cd105a-4 and cd105a-5, along with the positive control, Listeriolysin O (LLO) H-2K d CTL epitope peptide, resulted in an increase in IFN-producing spot-forming cells only in the splenocytes from Lm-LLO-CD105A-vaccinated mice (Supplemental Fig. 1b) . While this suggests that vaccination with Lm-LLO-CD105A can generate CD105-speciWc immune responses, further work will be needed in order to conWrm and characterize the speciWc CTL epitope(s) involved.
As previous work has demonstrated, eVective immunotherapy targeting the tumor vasculature is dependent upon epitope spreading [6] . Epitope spreading is a phenomenon wherein processing of dead tumor cells leads to secondary tumor-speciWc CD8 + T cell responses. To determine whether Lm-LLO-CD105A and Lm-LLO-CD105B are inducing epitope spreading in tumor-bearing mice, tetramer analysis was performed by Xow cytometry to inspect mice for stimulation of CD8 + T cells speciWc for two endogenous breast tumor antigens, Her-2/neu and gp70. Gp70 is an endogenous ecotropic murine leukemia provirus gene product that is expressed on a wide variety of murine tumors [43 and Beatty and Paterson, unpublished observations]. In the spleens of NT-2 tumor-bearing CD105-vaccinated mice, signiWcant stimulation of CTLs speciWc for two separate epitopes of Her-2/neu, EC1 and EC2, was observed in comparison with naïve and control-vaccinated mice (Fig. 5a) . Similarly, inspection of NT-2 tumor-inWltrating CD8 + T cells demonstrates signiWcant increases in the percentage of CTLs speciWc for three separate epitopes of Her-2/neu in comparison with control mice (Fig. 5b) . The same study was performed in 4T1-Luc tumor-bearing mice after vaccination. While the spleens of CD105-vaccinated mice only show signiWcant increases in the percentage of CD8 + T cells speciWc for one epitope of Her-2/neu (Fig. 5c) , the tumors of these mice have signiWcantly increased percentages of CD8 + T cells speciWc for of all three Her-2/neu epitopes inspected and for gp70 (Fig. 5d) . Taken together these results demonstrates that Lm-LLO-CD105A and B can signiWcantly stimulate epitope spreading to endogenous tumor antigens that may partially explain their eVectiveness in each of these tumor models.
To determine whether the anti-tumor eYcacy of each of our CD105 vaccines is due to the ability of each vaccine to disrupt tumor vasculature, expression of the vascular endothelium-speciWc protein, CD31, was assayed as a determination of vascular coverage [44] . After implantation and subsequent vaccination, NT-2 and 4T1-Luc tumors were excised and total tumor mRNA puriWed. After cDNA conversion, qPCR analysis was performed to determine the impact of each vaccine on tumor-speciWc expression of CD31. In comparison with control vaccination, Lm-LLO-CD105A and B each signiWcantly reduced tumor-speciWc expression of CD31 in both the NT-2 (Fig. 6a) and the 4T1-Luc (Fig. 6b) tumor models. As an additional measure of tumor vascularization, the hemoglobin concentration of tumor red blood cell lysate was assayed. In the NT-2 tumor model, Lm-LLO-CD105A vaccination resulted in signiWcant reduction in the concentration of tumor-speciWc hemoglobin while vaccination with Lm-LLO-CD105B demonstrated a trend toward a signiWcant reduction (P = 0.07) (Fig. 6c) . Similarly, in the 4T1-Luc tumor model, each CD105 vaccine signiWcantly reduced tumorspeciWc hemoglobin concentration in comparison with control vaccination (Fig. 6d) . The signiWcant reduction in expression of CD31 expression and reduced concentration of tumor-speciWc hemoglobin concentration suggest that each CD105 vaccine eVectively targets tumor neovascularization, likely resulting in their signiWcant eYcacy against primary and metastatic tumors.
Discussion
Numerous studies conWrm that high expression of CD105 is associated with tumor neovascularization [29-31, 45, 46] . While there have been attempts to target the elevated expression of CD105 found in tumor vasculature, a CTLmediated approach using Listeria-based vaccines could be one of the most eVective strategies [10, 32, 33] . After optimizing the vaccines for proWcient expression and secretion of recombinant CD105 fusion proteins, each of the vaccines signiWcantly inhibited growth of implanted primary tumors and signiWcantly limited metastatic spread, while Lm-LLO-CD105A signiWcantly delayed time to occurrence of autochthonous mammary tumors (Figs. 1, 2) . The relatively higher eYcacy of Lm-LLO-CD105A compared with Lm-LLO-CD105B in several assays (Figs. 2b, 4b, c, 6c ) may be explained by the more proWcient secretion of antigen by Lm-LLO-CD105A (Fig. 1b) . Additionally, with regard to reducing primary tumor growth, Listeria-based vaccines targeting CD105 expression on tumor vasculature are either equal or superior to vaccines targeting other tumor vasculature antigens (Fig. 3) . The results presented in this manuscript suggest that targeting elevated expression of CD105 on tumor vasculature with Listeria-based vectors results in signiWcant anti-tumor immune responses and signiWcant reductions in established primary and metastatic tumor growth.
Previous eVorts to target elevated CD105 expression on tumor vasculature have resulted in favorable outcomes [10, [32] [33] [34] . Several studies employed a passive immunotherapy approach by conjugating anti-CD105 mAbs to either a toxin, deglycosylated ricin A-chain (dgRA), or a radioactive isotope, 125 I [32, 33] . Each of these methods resulted in signiWcant growth suppression of tumors, however, if translated to the clinic, would likely require indeWnite injections due to the absence of adaptive immune responses. Alternatively, a DNA-based vaccine strategy was employed by Lee et al. [10] to target tumor vasculature for killing by CTLs. In this strategy, a plasmid encoding for CD105 is delivered to lymphoid organs by an attenuated Salmonella typhimurium vector. Prophylactic vaccination with this DNA-based CD105 vaccine led to CD8 + T cell-dependent responses that resulted in reduced tumor growth and reduced metastases after tumor challenge. However, our approach has several advantages over these prior studies. While a similar approach was taken by Lee et al. to stimulate the induction of CD105-speciWc CTL responses, we have taken the more clinically relevant and challenging approach of treating already established tumors in a therapeutic setting. While established tumors (>125 mm 3 ) are known to reside in a highly immunosuppressive microenvironment, complete tumor regression was observed in 37.5% of Lm-LLO-CD105A and 25% of Lm-LLO-CD105B-vaccinated mice at experiment end (Fig. 3a, c) [47, 48] . A great deal of this eVectiveness is likely due to the ability of our vector, attenuated Listeria, to break tolerance and elicit a robust CTL response to Listerial-secreted recombinant proteins [49] .
As with other anti-angiogenic therapies, there is an inherent safety concern regarding oV-target complications in healthy tissues [50, 51] . However, this is of less concern when targeting endoglin compared with other vascular markers since whole animal imaging studies using radiolabeled anti-CD105 mAbs have demonstrated that expression of CD105 is speciWc for vasculature associated with tumors [46] . This tumor-speciWc expression of CD105 may be because vascular endothelial cells weakly express CD105, while vascular endothelial cells undergoing proliferation highly express CD105 [29-31, 45, 46] . In addition to tumor-speciWc expression of CD105, anti-angiogenesis therapies have a greater impact on tumor vasculature because of the disorganized structure of rapid neovascularization [52] . In support of this argument, multiple intravenous injections of non-human primates with monoclonal antibody targeting CD105 had no detrimental impact on animal health [53] . In fact, previous anti-angiogenesis Listeria-based vaccines have demonstrated no signiWcant impact on pregnancy or wound healing, which are two normal processes that are highly dependent on neovascularization [6, 7] . While safety issues are always a concern before and during clinical testing, we believe the evidence suggests it is reasonable to expect few complications from immunotherapy targeting CD105.
As demonstrated in this manuscript, Listeria-based vaccines targeting CD105 limit the growth of established and metastatic breast tumors. Additionally, vaccination against CD105 with our Listeria-based vaccines resulted in the stimulation of tumor-speciWc CTLs that inWltrated tumors and likely facilitated the observed anti-tumor responses and reduction in tumor vascularization. Translation of these results into the clinic may require some modiWcation to the route of vaccine administration, as intravenous injection may be more acceptable than intraperitoneal injection. Previous studies, however, demonstrate that Listeria-based vaccines are still highly eVective when administered intravenously in both preclinical and clinical settings of cancer [54, 55] . Therefore, vaccination with Listeria-based CD105 vaccines may be a promising novel strategy to target neovascularization in tumor immunotherapy.
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